68 related articles for article (PubMed ID: 1578132)
1. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential.
Isaacs JD; Clark MR; Greenwood J; Waldmann H
J Immunol; 1992 May; 148(10):3062-71. PubMed ID: 1578132
[TBL] [Abstract][Full Text] [Related]
2. Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allograft survival and suppression of alloantibody production in mice.
Rashid A; Auchincloss H; Sharon J
J Immunol; 1992 Mar; 148(5):1382-8. PubMed ID: 1538121
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
4. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
5. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
7. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.
Isaacs JD; Greenwood J; Waldmann H
J Immunol; 1998 Oct; 161(8):3862-9. PubMed ID: 9780151
[TBL] [Abstract][Full Text] [Related]
8. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
[TBL] [Abstract][Full Text] [Related]
9. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
11. A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha.
Brüggemann M; Teale C; Clark M; Bindon C; Waldmann H
J Immunol; 1989 May; 142(9):3145-50. PubMed ID: 2496159
[TBL] [Abstract][Full Text] [Related]
12. Structural motifs involved in human IgG antibody effector functions.
Greenwood J; Clark M; Waldmann H
Eur J Immunol; 1993 May; 23(5):1098-104. PubMed ID: 8477804
[TBL] [Abstract][Full Text] [Related]
13. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
[TBL] [Abstract][Full Text] [Related]
14. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
15. Antibody-induced lysis of isolated rat epididymal adipocytes and complement activation in vivo.
Dickinson K; North TJ; Telford G; Smith SE; Edwards BM; Main SH; Field R; Hatton D; Vaughan TJ; Flint DJ; Jones RB
Obes Res; 2002 Feb; 10(2):122-7. PubMed ID: 11836458
[TBL] [Abstract][Full Text] [Related]
16. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
17. Use of hybridoma immunoglobulin switch variants in the analysis of the protective properties of anti-lipopolysaccharide antibodies in Escherichia coli K1 infection.
Pelkonen S; Pluschke G
Immunology; 1989 Oct; 68(2):260-4. PubMed ID: 2680911
[TBL] [Abstract][Full Text] [Related]
18. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Helfand SC; Hank JA; Gan J; Sondel PM
Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
[TBL] [Abstract][Full Text] [Related]
19. Complement-dependent synergistic effects of rat monoclonal IgG antibodies in vivo.
Yousaf N; Howard JC; Williams BD
Eur J Immunol; 1993 Feb; 23(2):369-75. PubMed ID: 7679641
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions.
Taylor L; Bachler M; Duncan I; Keen S; Fallon R; Mair C; McDonald TT; Schwarz H
J Leukoc Biol; 2002 Sep; 72(3):522-9. PubMed ID: 12223520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
